moxifloxacin has been researched along with simvastatin in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (simvastatin) | Trials (simvastatin) | Recent Studies (post-2010) (simvastatin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 8,442 | 1,730 | 3,630 |
| Protein | Taxonomy | moxifloxacin (IC50) | simvastatin (IC50) |
|---|---|---|---|
| photoreceptor-specific nuclear receptor | Homo sapiens (human) | 1.164 | |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | 4.426 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.7843 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 9.5 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0034 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0111 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.049 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 6.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C | 1 |
1 review(s) available for moxifloxacin and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and simvastatin
| Article | Year |
|---|---|
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Topics: Adult; Asian People; Cytochrome P-450 CYP2C9; Fluoroquinolones; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Male; Meloxicam; Moxifloxacin; Polymorphism, Genetic; Simvastatin; Thiazines; Thiazoles; White People; Young Adult | 2016 |
3 other study(ies) available for moxifloxacin and simvastatin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |